Trials / Active Not Recruiting
Active Not RecruitingNCT06180889
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
An Open, Randomized, Active-comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of Different Doses of KN060 for the Prevention of Venous Thromboembolism in Patients Undergoing Unilateral Total Knee Arthroplasty.
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 241 (actual)
- Sponsor
- Suzhou Alphamab Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin | 40 mg enoxaparin administered as subcutaneous injection once daily |
| DRUG | KN060 Low | Single dose of KN060 administered as intravenous infusion |
| DRUG | KN060 Middle | Single dose of KN060 administered as intravenous infusion |
| DRUG | KN060 Hight | Single dose of KN060 administered as intravenous infusion |
Timeline
- Start date
- 2023-12-20
- Primary completion
- 2025-12-15
- Completion
- 2026-04-15
- First posted
- 2023-12-26
- Last updated
- 2025-09-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06180889. Inclusion in this directory is not an endorsement.